NTRK1 and acute myeloid leukemia: This is illustrated further in Fig 6B, which examines the survival of patients diagnosed with AML not otherwise specified (NOS) according to the mutation status of the tyrosine kinase receptor FLT3 – those with the mutation had a significantly poorer survival than those without it (P = 0·006).